The focus of our lab is to identify the somatic genomic abnormalities that mediate cancer development or progression or influence how tumors respond to therapy. We are particularly focused on discovering abnormalities that lead to distinct clinical phenotypes and reveal mechanisms of molecular pathogenesis.
Barry S. Taylor, PhD
Associate Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
Research FocusResearcher Barry Taylor focuses on defining the somatic abnormalities that mediate the genesis, progression, and response to therapy of human cancers.
- PhD, Weill Cornell Medical College
- Al-Ahmadie H, Iyer G, Hohl M, Asthana S, Schultz N, Hanrahan AJ, Scott SN, Brannon AR, McDermott GC, Pirun M, Ostrovnaya I, Kim P, Socci ND, Viale A, Schwartz GK, Reuter V, Bochner B, Rosenberg JE, Bajorin DF, Berger MF, Petrini JH**, Solit DB**, Taylor BS**. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlie outlier response to cancer therapy. Cancer Discov. In press
- Johnson BE, Mazor T, Hong C, Barnes M, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Aihara K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, Cha S, Zhao Y, Moore RA, Mungal AJ, Jones SJM, Hirst M, Marra MA, Mukasa A, Saito N, Aburatani H, Berger MS, Chang SM, Taylor BS**, Costello JF**. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science, 2014; 343(6167): 189-93.
- Josie Robertson Investigator, Memorial Sloan Kettering Cancer Center (2014)
- Distinguished Scientist Award, Sontag Foundation (2013)
- Young Investigator Award, Prostate Cancer Foundation (2011)
- Young Investigator Award, Connective Tissue Oncology Society (2009)